miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

被引:426
作者
Kano, Masayuki [2 ]
Seki, Naohiko [1 ]
Kikkawa, Naoko
Fujimura, Lisa [3 ]
Hoshino, Isamu [2 ]
Akutsu, Yasunori [2 ]
Chiyomaru, Takeshi [4 ]
Enokida, Hideki [4 ]
Nakagawa, Masayuki [4 ]
Matsubara, Hisahiro [2 ]
机构
[1] Chiba Univ, Dept Funct Genom, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan
[2] Chiba Univ, Dept Frontier Surg, Grad Sch Med, Chiba 2608670, Japan
[3] Chiba Univ, Biomed Res Ctr, Chiba 2608670, Japan
[4] Kagoshima Univ, Dept Urol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan
关键词
microRNA; miR-145; miR-133a; miR-133b; esophageal squamous cell carcinoma; FSCN1; LYMPH-NODE DISSECTION; MICRORNA EXPRESSION; FASCIN; ADENOCARCINOMA; PROFILES; GENOMICS; LUNG;
D O I
10.1002/ijc.25284
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
MicroRNAs (miRNAs), noncoding RNAs 21-25 nucleotides in length, regulate gene expression primarily at the posttranscriptional level. Growing evidence suggests that miRNAs are aberrantly expressed in many human cancers, and that they play significant roles in carcinogenesis and cancer progression. A search for miRNAs with a tumor-suppressive function in esophageal squamous cell carcinoma (ESCC) was performed using the miRNA expression signatures obtained from ESCC clinical specimens. A subset of 15 miRNAs was significantly downregulated in ESCC. A comparison of miRNA signatures from ESCC and our previous report identified 4 miRNAs that are downregulated in common (miR-145, miR-30a-3p, miR-133a and miR-133b), suggesting that these miRNAs are candidate tumor suppressors. Gain-of-function analysis revealed that 3 transfectants (miR-145, miR-133a and miR-133b) inhibit cell proliferation and cell invasion in ESCC cells. These miRNAs (miR-145, miR-133a and miR-133b), which have conserved sequences in the 3'UTR of FSCN1 (actin-binding protein, Fascin homolog 1), inhibited FSCN1 expression. The signal from a luciferase reporter assay was significantly decreased at 2 miR-145 target sites and 1 miR-133a/b site, suggesting both miRNAs directly regulate FSCN1. An FSCN1 loss-of-function assay found significant cell growth and invasion inhibition, implying an FSCN1 is associated with ESCC carcinogenesis. The identification of tumor-suppressive miRNAs, miR-145, miR-133a and miR-133b, directly control oncogenic FSCN1 gene. These signal pathways of ESCC could provide new insights into potential mechanisms of ESCC carcinogenesis.
引用
收藏
页码:2804 / 2814
页数:11
相关论文
共 35 条
[1]   Roles of fascin in cell adhesion and motility [J].
Adams, JC .
CURRENT OPINION IN CELL BIOLOGY, 2004, 16 (05) :590-596
[2]   Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus [J].
Altorki, N ;
Kent, M ;
Ferrara, C ;
Port, J .
ANNALS OF SURGERY, 2002, 236 (02) :177-183
[3]   The functions of animal microRNAs [J].
Ambros, V .
NATURE, 2004, 431 (7006) :350-355
[4]  
Bancewicz J, 2002, LANCET, V359, P1727
[5]   Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues [J].
Bandres, E. ;
Cubedo, E. ;
Agirre, X. ;
Malumbres, R. ;
Zarate, R. ;
Ramirez, N. ;
Abajo, A. ;
Navarro, A. ;
Moreno, I. ;
Monzo, M. ;
Garcia-Foncillas, J. .
MOLECULAR CANCER, 2006, 5 (1)
[6]   MicroRNAs: Genomics, biogenesis, mechanism, and function (Reprinted from Cell, vol 116, pg 281-297, 2004) [J].
Bartel, David P. .
CELL, 2007, 131 (04) :11-29
[7]   MicroRNA signatures in human cancers [J].
Calin, George A. ;
Croce, Carlo M. .
NATURE REVIEWS CANCER, 2006, 6 (11) :857-866
[8]   Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? [J].
Chan, A ;
Wong, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02) :265-270
[9]  
CHO SC, 2009, EUR J CANCER, V45, P2197
[10]   From cancer genomics to thoracic oncology: Discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma [J].
Daigo Y. ;
Nakamura Y. .
General Thoracic and Cardiovascular Surgery, 2008, 56 (2) :43-53